Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Bayer, Bristol-Myers, Ono Partner for Colorectal Cancer Study

Bayer, Bristol-Myers Squibb and Ono Pharmaceutical teamed up to study the most common type of metastatic colorectal cancer.

Read More »

Genmab Raises $506 Million in IPO

Copenhagen, Denmark-based Genmab A/S raised $506 million with an initial public offering (IPO), with the company trading on the Nasdaq under the ticker symbol GMAB.

Read More »

Lung Ambition Alliance launches with goal to double five-year survival in lung cancer by 2025

The IASLC, Guardant Health, the Global Lung Cancer Coalition and AstraZeneca announced the Lung Ambition Alliance, a new partnership to eliminate lung cancer as a cause of death.

Read More »

Century Therapeutics Launches with $250 Million for Induced Pluripotent Stem Cell Platform

Century Therapeutics, a startup founded by Versant Ventures, launched with $250 million in hand and a focus on developing induced pluripotent stem cell-based therapies for the treatment of hematologic and solid malignancies.

Read More »

Genmab and Janssen Team Up to Develop Next-Generation CD38 Antibody

Denmark-based Genmab A/S and Janssen Biotech will collaborate on a successor to the multiple myeloma drug Darzalex with the development of a next-generation CD38 antibody product for the treatment of multiple myeloma and diffuse large B-cell lymphoma.

Read More »

W2O Announces Investment from New Mountain Capital; Partnership Focused on Making the World a Healthier Place through Marketing Communications

W2O announced a partnership with New Mountain Capital to accelerate continued growth and scale of the company to meet the evolving needs of its clients to most effectively and efficiently communicate with and influence their key stakeholders in an increasingly digital and mobile world.

Read More »

Gilead teams up with insitro for experimental NASH treatments

Gilead Sciences Inc. will partner with privately held insitro to develop therapies for a fatty liver disease called NASH.

Read More »

Novo Nordisk, Gilead team up to test NASH treatment

Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease known as NASH.

Read More »

Eisai Starts Phase III Trials for Second Alzheimer’s Drug After First’s Failure

Eisai Co. Ltd. initiated Phase 3 clinical trials of the Alzheimer’s treatment BAN2401 one day after the Japanese drugmaker and U.S. partner Biogen Inc. scrapped studies for the Alzheimer’s drug aducanumab.

Read More »

Universal Medica Group and EVERSANA announce global medical information and pharmacovigiliance service partnership

Universal Medica Group and EVERSANA announced a definitive partnership, increasing their global footprint and enhancing their expertise in the life sciences and healthcare industry.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom